Latest News and Press Releases

First-in-human healthy volunteers trial showed SYX-5219 was safe and well toleratedSystemic immunomodulation of type 2 inflammation demonstrated with reduction in serum CCL17/TARC Phase 1b trial in...

NORTH BRUNSWICK, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering clinical-stage biotech company developing innovative therapies for inflammatory diseases, announces a...

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead program afimetoran, a potential...

Oxford, UK and Boston, MA – March 26, 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune and...

The preclinical, small molecule program offers a potential first-in-class, oral, precision immunometabolic approach to modulating disease-driving immune cellsDeal includes upfront and milestone...

Oxford, UK and Boston, MA – February 19, 2026 – Sitryx Therapeutics (“the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in autoimmune...

Sitryx advances development of PKM2 modulator SYX-5219 into atopic dermatitis patients following clinical evidence of immunomodulatory activity First-in-class, oral PKM2 modulator, SYX-5219, has the...

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the feasibility of intravenous and subcutaneous dosing regimens in...

Favorable safety, tolerability, pharmacokinetic and pharmacodynamic profiles validate and significantly de-risk the programSupports the feasibility of intravenous and subcutaneous dosing regimens in...

Oxford, UK and Boston, MA – January 6, 2026 – Sitryx Therapeutics (“Sitryx” or “the Company”), a clinical-stage biopharmaceutical company developing novel oral therapies to restore immune balance in...